Changes in Hong Kong stocks | Jinhai Medical Technology (02225) rose more than 5%, earnings in the first half of the year increased sharply by more than 1.3 times year on year, and the strategic focus shifted to a high-value-added medical device circuit

The Zhitong Finance App learned that Jinhai Medical Technology (02225) rose by more than 5%. As of press release, it had risen 4.08% to HK$4.72, with a turnover of HK$6.287,400.

According to the news, recently, Jinhai Medical Technology revealed its 2026 interim results. Judging from the operating results, the pace of the company's revenue expansion has accelerated, and the quality of profit has improved simultaneously. In the first half of 2026, the Group achieved revenue of SGD 34.21 million, a sharp increase of 134.16% over the previous year, showing strong sales growth momentum.

On the business side, in the first half of 2026, the company's revenue structure was significantly optimized, and the strategic focus has successfully shifted from traditional labor services to a high-value-added medical device circuit. The share of revenue from minimally invasive surgical solutions, medical products and related service fees has climbed to 74.73%, making it a well-deserved new revenue pillar. Following a good increase in medical device sales revenue in 2025, the business's revenue surged 301.5% year-on-year in the first half of 2026 to reach SG$25.427 million, with sufficient momentum for sustainable growth.